Arix Bioscience Plc Arix notes Iterum?s proposed US IPO (8795M)
May 02 2018 - 4:10AM
UK Regulatory
TIDMARIX
RNS Number : 8795M
Arix Bioscience Plc
02 May 2018
Arix Bioscience plc
Iterum announces confidential submission of draft registration
statement for proposed initial public offering in the United
States
2 May 2018 Arix Bioscience plc (LSE:ARIX) ("Arix"), a global
healthcare and life science company supporting medical innovation,
today notes that its Group Business Iterum Therapeutics ("Iterum")
has submitted a registration statement on Form S-1 to the US
Securities and Exchange Commission relating to a proposed initial
public offering ("IPO") of ordinary shares in the United States.
Iterum has applied to list its ordinary shares on the Nasdaq Global
Select Market under the symbol "ITRM." The timing and the terms of
this proposed initial public offering have not yet been determined
and are subject to market conditions and other factors.
ENDS
For more information on Arix, please contact:
Arix Bioscience plc
Charlotte Parry, Investor Relations Manager
+44 (0)20 7290 1072
charlotte@arixbioscience.com
Consilium Strategic Communications
Mary-Jane Elliott, Jessica Hodgson, Ivar Milligan
+44 (0)20 3709 5700
arix@consilium-comms.com
About Arix Bioscience plc
Arix Bioscience plc is a global healthcare and life science
company supporting medical innovation. Headquartered in London and
with an office in New York, Arix Bioscience sources, finances and
builds world class healthcare and life science businesses
addressing medical innovation at all stages of development.
Operations are supported by privileged access to breakthrough
academic science and strategic relationships with leading research
accelerators and global pharmaceutical companies.
Arix Bioscience plc is listed on the Main Market of the London
Stock Exchange. For further information, please visit
www.arixbioscience.com
About Iterum Therapeutics plc
Iterum Therapeutics plc (Iterum Therapeutics) is an Irish
clinical-stage pharmaceutical company dedicated to developing
differentiated anti-infectives aimed at combatting the global
crisis of multi-drug resistant pathogens to significantly improve
the lives of people affected by serious and life-threatening
diseases around the world. Iterum Therapeutics is advancing its
first compound, sulopenem, a novel penem anti-infective compound
with oral and IV formulations that has demonstrated potent in vitro
activity against a wide variety of gram-negative, gram-positive and
anaerobic bacteria resistant to other antibiotics. Iterum
Therapeutics has received QIDP designations for its oral and IV
formulations for the treatment of uUTI, cUTI and cIAI. Iterum
Therapeutics is led by a highly experienced team and backed by a
blue-chip venture capital syndicate. For more information, please
visit www.iterumtx.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCLIFIAEAIFIIT
(END) Dow Jones Newswires
May 02, 2018 05:10 ET (09:10 GMT)
Arix Bioscience (LSE:ARIX)
Historical Stock Chart
From Apr 2024 to May 2024
Arix Bioscience (LSE:ARIX)
Historical Stock Chart
From May 2023 to May 2024